- Home
- VRDN
as 12-17-2024 4:00pm EST
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.6B | IPO Year: | N/A |
| Target Price: | $37.63 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.40 - $27.20 | Next Earning Date: | 11-12-2024 |
| Revenue: | $302,000 | Revenue Growth: | -12.97% |
| Revenue Growth (this year): | 2.55% | Revenue Growth (next year): | -26.93% |
Stock Insider Trading Activity of Viridian Therapeutics Inc. (VRDN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Beetham Thomas W. | VRDN | Chief Operating Officer | Sep 27 '24 | Buy | $23.41 | 5,000 | $117,050.00 | 6,000 | |
| Mahoney Stephen F. | VRDN | President and CEO | Sep 27 '24 | Buy | $23.33 | 21,400 | $499,262.00 | 21,400 |
Latest Viridian Therapeutics Inc. News
VRDN Breaking Stock News: Dive into VRDN Ticker-Specific Updates for Smart Investing
TipRanks
a day ago
Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints
Investor's Business Daily
2 days ago
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen
Investor's Business Daily
2 days ago
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
Business Wire
2 days ago
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
Business Wire
5 days ago
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
Business Wire
14 days ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
a month ago
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Business Wire
a month ago
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
Compare VRDN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRDN Viridian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.